ING Knock-Out RO/ DE000NG8RW75 /
2024-10-10 4:42:26 PM | Chg.+0.280 | Bid4:55:08 PM | Ask4:55:08 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
17.070EUR | +1.67% | 17.060 Bid Size: 10,000 |
17.110 Ask Size: 10,000 |
ROCHE I | 129.0315 CHF | 2078-12-31 | Call |
Newsfile Corp
10-02
First Phosphate Corp. communique la publication d'une note de recherche universitaire relative aux g...
GlobeNewswire
06-18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06-14
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon...
GlobeNewswire
05-09
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
04-03
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire
04-02
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
03-14
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire
02-26
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire
01-03
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...
GlobeNewswire
01-03
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Tria...
GlobeNewswire
2023-12-29
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
GlobeNewswire
2023-12-14
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibo...